![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Cogentin, others |
Other names | benzatropine (BAN UK), benztropine (USAN US) |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intramuscular, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Liver |
Elimination half-life | 12–24 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H25NO |
Molar mass | 307.437 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Benzatropine (INN[2]), known as benztropine in the United States and Japan,[3] is a medication used to treat movement disorders like parkinsonism and dystonia, as well as extrapyramidal side effects of antipsychotics, including akathisia.[4] It is not useful for tardive dyskinesia.[4] It is taken by mouth or by injection into a vein or muscle.[4] Benefits are seen within two hours and last for up to ten hours.[5][6]
Common side effects include dry mouth, blurry vision, nausea, and constipation.[4] Serious side effect may include urinary retention, hallucinations, hyperthermia, and poor coordination.[4] It is unclear if use during pregnancy or breastfeeding is safe.[7] Benzatropine is an anticholinergic which works by blocking the activity of the muscarinic acetylcholine receptor.[4]
Benzatropine was approved for medical use in the United States in 1954.[4] It is available as a generic medication.[4] In 2020, it was the 229th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[8][9] It is sold under the brand name Cogentin among others.[4]